ROCKAWAY, N.J. , Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers
ROCKAWAY, N.J. , Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimulation (nVNS)
As of December 7, 2022 As you may know, the Board of Directors of electroCore, Inc. recently declared a stock dividend for our common stockholders. The dividend of Series A Preferred Stock is expected to be issued later this month to holders of record as of December 19, 2022.
ROCKAWAY, N.J. , Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called Truvaga TM for customers residing in the United States .
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022 Revenue growth of approximately 57% over full-year 2021 Launched two new brands; TAC-STIM ™ under the Air Force BOOST program and Truvaga ™ wellness product for stress,
ROCKAWAY, N.J. , Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15.
ROCKAWAY, N.J. , Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology
ROCKAWAY, N.J. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents and intends to issue a third new patent related to
ROCKAWAY, N.J. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with Byond Healthcare Pty Ltd. to serve as the exclusive distributor of gammaCore Sapphire TM ,
ROCKAWAY, N.J. , March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2022 , after the close of the market on